Literature DB >> 15644414

CD19 regulates positive selection and maturation in B lymphopoiesis: lack of CD19 imposes developmental arrest of immature B cells and consequential stimulation of receptor editing.

Eran Diamant1, Zohar Keren, Doron Melamed.   

Abstract

Ligand-independent signals that are produced by the B-cell antigen receptor (BCR) confer an important positive selection checkpoint for immature B cells. Generation of inappropriate signals imposes developmental arrest of immature B cells, though the fate of these cells has not been investigated. Studies have shown that the lack of CD19 results in inappropriate signaling. In immunoglobulin transgenic mice, this inappropriate signaling impairs positive selection and stimulates receptor editing. Here, we studied the extent and significance of receptor editing in CD19-regulated positive selection of normal, nontransgenic B lymphopoiesis, using our bone marrow culture system. We found that the lack of CD19 resulted in elevated tonic signaling and impaired maturation, as revealed by surface marker expression and by functional assays. Immature CD19-/- B cells did not suppress RAG and underwent intensive receptor editing attempts in culture. Finally, in vivo analysis of light-chain isotype expression and Jkappa use in CD19-/- mice validated our in vitro observations. Our results suggest that CD19 has an important function in regulating positive selection and maturation of nontransgenic B-cell precursors and that receptor editing is an important salvage mechanism for immature B cells that fail positive selection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15644414     DOI: 10.1182/blood-2004-08-3165

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  17 in total

1.  N-Glycan Branching Is Required for Development of Mature B Cells.

Authors:  Christie-Lynn Mortales; Sung-Uk Lee; Michael Demetriou
Journal:  J Immunol       Date:  2020-06-26       Impact factor: 5.422

2.  Central B-cell tolerance: where selection begins.

Authors:  Roberta Pelanda; Raul M Torres
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-04-01       Impact factor: 10.005

3.  The transcription factor Bright plays a role in marginal zone B lymphocyte development and autoantibody production.

Authors:  Athenia L Oldham; Cathrine A Miner; Hong-Cheng Wang; Carol F Webb
Journal:  Mol Immunol       Date:  2011-10-02       Impact factor: 4.407

Review 4.  Regulation of B-cell proliferation and differentiation by pre-B-cell receptor signalling.

Authors:  Sebastian Herzog; Michael Reth; Hassan Jumaa
Journal:  Nat Rev Immunol       Date:  2009-03       Impact factor: 53.106

5.  Suppression of phosphatidylinositol 3,4,5-trisphosphate production is a key determinant of B cell anergy.

Authors:  Cecille D Browne; Christopher J Del Nagro; Matthew H Cato; Hart S Dengler; Robert C Rickert
Journal:  Immunity       Date:  2009-11-05       Impact factor: 31.745

6.  Activation of Ras overcomes B-cell tolerance to promote differentiation of autoreactive B cells and production of autoantibodies.

Authors:  Lenka S Teodorovic; Chiara Babolin; Sarah L Rowland; Sarah A Greaves; David P Baldwin; Raul M Torres; Roberta Pelanda
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-23       Impact factor: 11.205

Review 7.  Aging and neoteny in the B lineage.

Authors:  Doron Melamed; David W Scott
Journal:  Blood       Date:  2012-08-30       Impact factor: 22.113

8.  The development of mature B lymphocytes requires the combined function of CD19 and the p110δ subunit of PI3K.

Authors:  Dorottya Kövesdi; Sarah E Bell; Martin Turner
Journal:  Self Nonself       Date:  2010-03-11

Review 9.  miRNAs in B Cell Development and Lymphomagenesis.

Authors:  Maryaline Coffre; Sergei B Koralov
Journal:  Trends Mol Med       Date:  2017-07-07       Impact factor: 11.951

10.  Basal B cell receptor-directed phosphatidylinositol 3-kinase signaling turns off RAGs and promotes B cell-positive selection.

Authors:  Laurent Verkoczy; Bao Duong; Patrick Skog; Djemel Aït-Azzouzene; Kamal Puri; José Luis Vela; David Nemazee
Journal:  J Immunol       Date:  2007-05-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.